Home › Companies › MIST

Milestone Pharmaceuticals

Market cap $51.4M 124.5M shares (10-Q, Nov 13, 2026) × $0.413 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. CARDAMYST PSVT EU decision1H 2027CARDAMYST PSVT EU decision, 1H 2027, material
  2. Restructuring corporate update1Q 2027Restructuring corporate update, 1Q 2027, routine
  3. MIST listing updateApr 21, 2027MIST listing update, Apr 21, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (2 active programs)

Capital (as filed)

Cash
$144M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$882K Sep 30, 2026
Operating cash flow
−$25.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$145M cash, runway late 2028 per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (10)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (11 calls)

Every verdict Biotech Distilled has published on Milestone Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Buy core Milestone Pharmaceuticals (MIST): Scientific Due Diligence for CARDAMYST (etripamil) and Pipeline FDA approval plus $75M non-dilutive cash infusion creates favorable risk/reward; science is validated, regulatory risk is off the table, and patent protection runs to 2042, with the main remaining risk being commercial launch execution.
  2. Buy core Update: MIST Goes Global. The Pocket Hospital Enters Europe. EMA acceptance of the TACHYMIST MAA adds a third pillar of strategic optionality and potential European partnership value on top of the intact U.S. launch thesis.
  3. Buy core UPDATE: Milestone Pharmaceuticals (MIST) - CARDAMYST is on the Shelf. The Clock Starts Now. CARDAMYST is now available at retail pharmacies with a $25 copay cap reducing patient financial friction; company is executing the launch playbook as promised.
  4. Buy core Update: Milestone Pharmaceuticals (MIST) - Building the Foundation for Launch (and Deals) New General Counsel hire with M&A and commercialization track record signals management is putting the right infrastructure in place for both the commercial rollout and potential European licensing deals.
  5. Buy core UPDATE: Milestone Pharmaceuticals (MIST) - $200M War Chest and Slaying the Hypotension Bear ~$200M pro-forma cash runway into late 2027 closes the dilution gap, ACC.26 data neutralizes the hypotension bear argument, and AFib-RVR Phase 3 is officially moving forward.
  6. Buy core UPDATE: Milestone Pharmaceuticals (MIST) - Express Scripts Says Yes, and the Stock Wakes Up Express Scripts formulary win inside 90 days of launch materially de-risks the step-edit bear case, and the RESET-PSVT real-world evidence registry builds both physician confidence and M&A optionality.
  7. Buy core UPDATE: Milestone Pharmaceuticals (MIST) - The First Scoreboard, and a Fresh $100M ATM ~400 unique prescribers in 10 weeks confirms breadth of launch adoption, but the new $100M Cantor ATM introduces dilution optionality that must be monitored; thesis intact if ATM remains untouched.
  8. Buy core UPDATE: Milestone Pharmaceuticals (MIST) - The Scoreboard Just Tripled and Nobody Noticed Scripts up ~5x QoQ, prescribers up 4x, covered lives doubling to ~50%, and the Cantor ATM untouched — all stated bull signals hit — while the stock fell 35%, creating a disconnect between improving operating metrics and price.
  9. Buy core UPDATE: Milestone Pharmaceuticals (MIST) - The Pocket Hospital Clears China NMPA approval independently replicates RAPID trial efficacy (HR 3.002 vs 2.62), adding a second regulatory green light and strengthening the EMA decision outlook while Everest commercializes at no incremental cost to Milestone.
  10. Hold UPDATE: Milestone Pharmaceuticals (MIST) - The Sub-Dollar Problem Downgrading from BUY to HOLD due to financing risk from Nasdaq bid-price deficiency notice, potential reverse split, and ATM that would now cost more than the entire share count at sub-$1 prices; awaiting Q3 print to reassess.
  11. Avoid UPDATE: Milestone Pharmaceuticals (MIST) - The Company Marked Down Its Own Launch Management's own implied sales forecast revision (RTW royalty rate drop from 19.03% to 5.59%), 30% opex cut, sales force reduction, and two C-suite exits signal the PSVT launch will not re-rate the stock; thesis now rests on a 2H 2028 AFib-RVR binary with dilution risk in between.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (29)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)